The firm is seeking marketing clearance for its Liaison NES real-time PCR instrument along with a multiplex test for flu A/B, COVID-19, and respiratory syncytial virus infection.

Broader macroeconomic uncertainty has resulted in continued caution for both investors and acquirers in the in vitro diagnostics sector.